First Pacific Financial Buys 1,418 Shares of Pfizer Inc. (NYSE:PFE)

First Pacific Financial raised its stake in Pfizer Inc. (NYSE:PFE) by 7.3% during the 4th quarter, Holdings Channel reports. The fund owned 20,716 shares of the biopharmaceutical company’s stock after acquiring an additional 1,418 shares during the period. First Pacific Financial’s holdings in Pfizer were worth $596,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp grew its stake in shares of Pfizer by 1.9% during the second quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after buying an additional 5,374,611 shares during the last quarter. Moneta Group Investment Advisors LLC raised its stake in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley raised its holdings in shares of Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after acquiring an additional 348,628 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $3,150,472,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PFE shares. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Friday, March 1st. Truist Financial reduced their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Finally, Barclays dropped their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

PFE stock opened at $27.77 on Thursday. The firm has a market capitalization of $157.25 billion, a P/E ratio of 77.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $27.47 and a two-hundred day simple moving average of $29.47. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. During the same quarter last year, the business posted $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.